3. Chart Number: 4. 9IS #: (UNOS use only) Father's I/C. I/C Guardian: Not available. (autofill if MyKad is available)
|
|
- Emily Farmer
- 6 years ago
- Views:
Transcription
1 provided, check ( ) one box only. NA refers to t Applicable. Fill in the date with ddmmyyyy format. SECTION 1 : PROVIDER INFORMATION 1a. Transplant Centre Provider Number: 1b. Transplant Centre Name : 2a. Follow-up Hospital Provider Number: 2b. Follow-up Hospital Name: 3. Chart Number: 4. 9IS #: (UNOS use only) SECTION 2 : RECIPIENT DETAILS 1. Name : (Please print in capital letters) 2. Registration Number: 3. NRIC : MyKad: - - Old IC: Other ID document : Specify document type (if others): <12 years: Birth cert # : Registration number Passport Mother's IC Father's IC IC Guardian: Mother Father Armed Force ID Work Permit # Date of Birth Lab number Sibling ranking: Others 4a. Date of Birth: 6. Ethnic group: If the exact date is not known, please enter 0107yyyy Malay Chinese Indian 7. Religion: Islam Buddhism Bumiputra Sabah, specify: (autofill if MyKad is available) 4b. Age: (autocalculate) Bumiputra Sarawak, specify: Others, specify:. 5. Gender: Male Female Christianity Hinduism Others, specify 8. Marital Status: Single Married Widowed Divorced 9. Education Level: Uneducated Primary Secondary Tertiary Others, specify 10. Date added to wait list: 11. Date of transplant: 12. State of residence: 13. Country of residence: 14. Immediate Pretransplant Employment status: Johor Darul Takzim Kedah Darul Aman Kelantan Darul Naim Melaka Negeri Sembilan Darul Khusus Pahang Darul Makmur Perak Darul Ridzuan Perlis Indera Kayangan Pulau Pinang Sabah Sarawak Selangor Darul Ehsan Terengganu Darul Iman Wilayah Persekutuan Kuala Lumpur Wilayah Persekutuan Labuan, Sabah Wilayah Persekutuan Putrajaya t applicable - Foreign Malaysia Others, specify : Student Working full time Working Part Time By Choice Working Part Time Due to Disease Working Part Time Reason t Working By Choice t Working Due to Disease SECTION 3 : IMMEDIATE PRETRANSPLANT CLINICAL INFORMATION 1. ABO Blood Group: 2. Weight (kg): 3. Height (cm): 4a. Heart diagnosis: t Working Unable to Find Employment A B AB O.. Ischaemic Cardiomyopathy Idiopathy Dilated Cardiomyopathy Other, specify Restrictive Cardiomyopathy End Stage valvular heart disease t Working, Reason Retired Employment Status Hypertrophic Cardiomyopathy 4b. Lung diagnosis specify: (Use Code) Version 1.11 last updated on Mandatory Fields Page 1
2 provided, check ( ) one box only. NA refers to t Applicable. Fill in the date with ddmmyyyy format. SECTION 3 : IMMEDIATE PRETRANSPLANT CLINICAL INFORMATION 5a. Medical condition: 5b. Patient on life support: (Continue) Patient in Intensive Care Uni Hospitalized, but not in Intensive Care Unit t hospitalized ECMO IABP hrs hrs PGE IV Inotropes Nasal Ventilation ninvasive Ventilation, CPAP ninvasive Ventilation, BiPAP Long Term Oxygen Therapy Other mechanism Specify: LVAD HeartMate IP HeartMate VE HeartMate II vacor PC vacor PCq Thoratec Arrow Lionheart HeartSaver VAD Micromed DeBakey Jarvik 2000 Pittsburgh AB180 Berlin Heart Medos Toyobo Type unspecified RVAD Thoratec Berlin Heart Medos Toyobo Abiomed BVS BioMedicus Type unspecified TAH Cardiowest AbioCor Type unspecified 5c. Date of implantation: 6. Functional Status: (How does the patient perform activities of daily living? Select one) activity limitations. (NYHA Class I or Class II) Performs activities of daily living with some assistance. (NYHA Class III) Performs activities of daily living with total assistance. (NYHA Class IV) NA Patient hospitalized 7. Pretransplant Serology: a. HIV Negative Positive b. CMV lgg: Negative Positive lgm: DNA: Negative Positive Negative Positive c. Hep B Core Antibody: Negative Positive Surface Antigen: HBV DNA: Negative Positive Negative Positive d. Hep C Antibody Screen: Negative Positive RIBA Test: HCV RNA: Negative Positive Negative Positive e. EBV IgG: Negative Positive lgm: DNA: f. Most recent Hemodynamics & Inotropes PA (sys) actual: PA (dia) estimate: PA (mean): PCW (mean): CO: Ejection Fraction: Negative Positive Negative Positive mmhg mmhg mmhg mmhg Lmin % Inotropes Inotropes Inotropes Inotropes Inotropes Inotropes Version 1.11 last updated on Mandatory Fields Page 2
3 provided, check ( ) one box only. NA refers to t Applicable. Fill in the date with ddmmyyyy format. SECTION 3 : IMMEDIATE PRETRANSPLANT CLINICAL INFORMATION 8a. Most recent Serum Creatinine: 8b. Most recent Serum Total Bilirubin: 8c. Oxygen requirement at rest: 8d. Chronic Steroid Use: µmoll µmoll Lmin (Continue) 8e. FEV1(L)FVC(L): 8f. po 2 on room air: on oxygen: 9. Pulmonary Status a. FVC: 10. General Medical Factors b. FEV1: c. pco2: % Predicted % Predicted mmhg a. Diabetes Diabetes Insulin Dependent Diabetes n-insulin Dependent Diabetes b. Dialysis Dialysis Hemodialysis c. Peptic Ulcer Disease, Drug Treated, t Drug Treated Diabetes, Dependency Peritoneal Dialysis, Drug Treatment 11. Heart Medical Factors d. Unstable Angina Coronary Artery Disease Myocardial Infarction: e. Drug Treated Systemic Hypertension: f. Symptomatic Cerebrovascular Disease Stable CAD Unstable CAD Old MI g. Symptomatic Peripheral Vascular Disease h. Drug Treated COPD i. Pulmonary Embolism (within last 6 months) j. Any Previous Transfusions : k. Any Previous Malignancy (Exclude non-melanoma skin cancer) l. PRA Negative Positive m. Any cigarette use within last 6 months a. Sudden Death b. Antiarrythmics c. Amiodarone d. Implantable defibrillator e. Cardiac Resynchronisation Therapy f. Exercise oxygen consumption: mlminkg Version 1.11 last updated on Mandatory Fields Page 3
4 provided, check ( ) one box only. NA refers to t Applicable. Fill in the date with ddmmyyyy format. SECTION 3 : IMMEDIATE PRETRANSPLANT CLINICAL INFORMATION (Continue) 12. Events Occuring to Listing for Transplant a. Pneumothorax b. Infection requiring IV drug therapy (within two weeks prior to listing) c. Left ventricular remodeling d. Pneumoreduction e. Transmyocardial revascularization (TMR) f. Sternotomy ne 1 +1 g. CABG h. Thoracotomy: Left i. Thoracotomy: Right j. Pleurodesis 13. Lung Medical Factors a. IV Treated Pulmonary Sepsis Episodes > 2 in last 12 months 14. HLA Typing: a. Method: b. Corticosteroid Dependency > 5 mgday c. Six minute walk distance < 150 ft. d. Pan-Resistant Bacterial Infection b. Typing: Serology DNA Other, specify: SECTION 4 : TRANSPLANT CLINICAL INFORMATION 1. Multiple Organ Recipient: check all organs that apply Liver Kidney Intestine Pancreas Pancreas Islets Bone Marrow 2a. Procedure Type: Ortho Heart Hetero Heart 2b. Procedure Information (Heart only): Orthotopic Bicaval Orthotopic Traditional Heart Lung Single Left Lung Single Right Lung Bilateral Sequential Lung Heterotopic En-Bloc Double Lung Others: 3. Total Organ Ischaemic Time: Heart Left Lung Heart - Lung Right Lung SECTION 5 : POST TRANSPLANT CLINICAL INFORMATION 1. Events Prior to Discharge: a. Any Drug Treated Rejection b. Any Drug Treated Infection c. Stroke d. Dialysis e. Re-Operation, Hemorrhage f. Re-Operation, Other g. Other Surgical Procedures h. Prolonged Graft Dysfunction i. Permanent Pacemaker j. Bronchopleural Fistula k. Airway Dehiscence Version 1.11 last updated on Mandatory Fields Page 4
5 provided, check ( ) one box only. NA refers to t Applicable. Fill in the date with ddmmyyyy format. SECTION 6 : PATIENT STATUS AT DISCHARGE 1. Patient Status a. Date of Report or Death b. Status: Living Dead Cause of Death: (Use code) Specify: Retransplanted prior to hospital discharge Ca Hyperacute Rejection Acute Rejection Other Lost 2. Transplant Hospitalization a. Date of discharge from transplant center b. Date of admission to transplant center c. Was patient transferred from another hospital prior to transplant? Date of admission to transferring hospital 2. Previous transplants? Kidney : Liver : Pancreas (whole) Pancreas (islet cells) Heart : : : Lung Intestine : : Bone Marrow : Version 1.11 last updated on Mandatory Fields Page 5
6 provided, check ( ) one box only. NA refers to t Applicable. Fill in the date with ddmmyyyy format. SECTION 7 : TREATMENT AT DISCHARGE 1. Immunosuppressive Information a. Did the patient participate in any clinical research protocol for immunosuppressive medications? Specify: 2. Other Therapy a. Photopheresis 3. Antivirals b. Plasmapheresis c. Total Lymphoid Irradiation (TLI) a. CMV Globulin b. Acyclovir (Zovirax) c. Ganciclovir (Cytovene) d. Other: SECTION 8 : DONOR INFORMATION 1. Donor's Name: 2. Donor's Age: 3. Donor's gender: Male Female 4. Donor's Ethnic group: Malay 5. Donor's Country: Malaysia Others, specify: 6. Donor Type: Cadaveric Living 7. Date of Organ Procurement 8. Donor's ABO Blood Group Chinese Indian Bumi Sabah Bumi Sarawak Others: A B AB O 9. a) Donor's Weight (kg): 9. b) Donor's Height (cm): 10. Donor's Cause of Death 11. Donor's Mechanism of Death AnoxiaCardiac Arrest Head Trauma Drowning Seizure Drug Intoxication Asphyxiation Cardiovascular Electrical CerebrovascularStroke CNS Tumor Gunshot Wound Stab Blunt Injury Sudden Infant death Other, specify: Intercranial Hemorrhage Stroke Death from Natural Causes 12. Donor's Serology a. Anti-HIV I Negative Positive b. Anti-HIV II c. Anti-HTVL I d. Anti-HTVL II Negative Positive Negative Positive Negative Positive e. RPR-VDRL Negative Positive f. Anti-CMV g. HBsAg h. Anti-HBC i. Anti-HCV j. EBV 13. Donor's HLA Typing: a. Method: Serology DNA b. Typing: Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive Other, specify: 14. Donor's History Of: a. Hypertension b. Diabetes c. Cancer d. Infection at time of Procurement e. Donor Coronary Disease MVA ne of the Above Version 1.11 last updated on Mandatory Fields Page 6
7 provided, check ( ) one box only. NA refers to t Applicable. Fill in the date with ddmmyyyy format. SECTION 9 : IMMUNOSUPPRESSION THERAPY 1. Steroids a. Prednisone b. Methylprednisolone 2. T-Cell Activation Inhibitors a. Cyclosporin A (CSA, Sandimmune, CyA, CyS) b. Neoral (CyA-NOF) c. FK506 (Prograf, Tacrolimus) d. Rapamycin (RAPA, Sirolimus, Rapamune) e. Gengraf 3. Antimetabolites a. Azathioprine (AZA, Imuran) b. Mycophenolate Mofetil (MMF, Cellcept, RS61443) c. Cytoxan (Cyclophosphamide) 4. Anti-Lymphocyte Receptor Antibodies d. Methotrexate (Folex, PFS, Mexate- AQ, Rheumatrex) a. T10B9 (Medimmune) b. ATG (Atgam, Anti-thymocyte Globulin) c. NRATG NRATS d. OKT3 (Orthoclone, Muromonab) e. Thymoglobulin f. Zenepax g. Simulect 5. Cytokine Inhibitors a. IL - 1 Receptor Antagonist b. Anti - IL - 6 c. Anti - TNF d. Soluble IL - 1 Receptor 6. Suppressor Inducers a. Aldesleukin (IL - 2) 7. Others, immunosuppressive medication, specify: Version 1.11 last updated on Mandatory Fields Page 7
CHAPTER 3 HEART AND LUNG TRANSPLANTATION. Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping
CHAPTER 3 Editors: Mr. Mohamed Ezani Hj Md. Taib Dato Dr. David Chew Soon Ping Expert Panel: Tan Sri Dato Dr. Yahya Awang (Chair) Mr. Mohamed Ezani Hj Md. Taib (Co-chair) Datin Dr. Aziah Ahmad Mahayiddin
More informationCHAPTER 8 CADAVERIC ORGAN AND TISSUE DONATION. Editor: Datin Dr Lela Yasmin Mansor
CHAPTER 8 Editor: Datin Dr Lela Yasmin Mansor Expert Panel Datin Dr Lela Yasmin Mansor (chairperson) Dr Hooi Lai Seong Dr Omar Sulaiman Dr Muhammed Anis Abdul Wahab Matron Jamaliah Kario Staff Nurse Santi
More informationRecords. Adult Kidney Pancreas Transplant Recipient Registration Worksheet. Recipient Information. Provider Information.
Records Adult Kidney Pancreas Transplant Recipient Registration Worksheet FORM APPROVED: O.M.B. NO. 0915 0157 Expiration Date: 07/31/2020 Note: These worksheets are provided to function as a guide to what
More informationChapter - 2 DIALYSIS IN MALAYSIA
2 th Report of the Malaysian Dialysis and Transplant Registry 212 Dialysis IN Malaysia Chapter - 2 DIALYSIS IN MALAYSIA Goh Bak Leong Lim Yam Ngo Ong Loke Meng Ghazali Ahmad Lee Day Guat Dialysis IN Malaysia
More informationDonor Height Centimeters Inches Missing Reason: Not Done Unknown. Donor Weight Kilograms Pounds Missing Reason: Not Done Unknown. Female Male Unknown
Page 1 of 6 Patient Details Hidden Show Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved Form 2: Donor Toggle Question Year/Info Print this Form t Started Transplant Date 1 Donor
More informationMonths Years. Centimeters Inches Missing Reason: Not Done Unknown. Kilograms Pounds Missing Reason: Not Done Unknown. Female Male Unknown
Form 2: Donor Print this Form t Started 1 2 Transplant Date Donor Age Indicate age in months, days, or years Days Months Years Donor Date of Birth Height and Weight 3 Donor Height Centimeters Inches t
More informationImmunosuppression: evolution in practice and trends,
American Journal of Transplantation 25; 5 (Part 2): 874 886 Blackwell Munksgaard Blackwell Munksgaard 25 Immunosuppression: evolution in practice and trends, 1993 23 Ron Shapiro a,, James B. Young b, Edgar
More informationCHAPTER 2. Dialysis in Malaysia
15th Report of the Malaysian Dialysis and Transplant Registry 27 DIALYSIS IN MALAYSIA CHAPTER 2 Dialysis in Malaysia Lim Yam Ngo Lim Teck Onn Lee Day Guat 4 DIALYSIS IN MALAYSIA 15th Report of the Malaysian
More information2/28/2017. Adult Heart Transplants Donor and Recipient Characteristics UNOS, Retransplant VCM. Other /2015 (N = 24,474)
1 46% 2% 3% 4% 0% 2% 2% CHD HCM ICM NICM RCM 49% 3% 3% 3% 1% 3% 3% Retransplant VCM 42% Other 35% 1/1982 6/2015 1/2009 6/2015 2016 JHLT. 2016 Oct; 35(10): 1149-1205 UNOS, 2017 Adult Heart Transplants Donor
More informationCHAPTER 1 PROVISION OF ACUTE CORONARY CARE SERVICES IN MALAYSIA
CHAPTER 1 PROVISION OF ACUTE CORONARY CARE SERVICES IN MALAYSIA Sim Kui Hian Wan Azman Wan Ahmad Robaayah Zambahari Chin Sze Piaw Jamaiyah Haniff Lim Teck Onn In 26, there were a total of 31186 admissions
More informationOverview of New Approaches to Immunosuppression in Renal Transplantation
Overview of New Approaches to Immunosuppression in Renal Transplantation Ron Shapiro, M.D. Professor of Surgery Surgical Director, Kidney/Pancreas Transplant Program Recanati/Miller Transplantation Institute
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationCardiac surgery - CAD
Cardiac surgery - CAD University of Pecs, Medical Faculty Heart Institute http://aok.pte.hu/en/egyseg/dokumentumok/290 Treatment strategies for CAD medical nitrate, anti-tct, (lysis), beta-blocker... interventional
More informationChapter 5 PAEDIATRIC RENAL REPLACEMENT THERAPY. Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin
Chapter 5 PAEDIATRIC RENAL REPLACEMENT THERAPY Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin SECTION A: RRT PROVISION FOR PAEDIATRIC PATIENTS This chapter presents
More informationTolerance Induction in Transplantation
Tolerance Induction in Transplantation Reza F. Saidi, MD, FACS, FICS Assistant Professor of Surgery Division of Organ Transplantation Department of Surgery University of Massachusetts Medical School Percent
More information06/04/2013 ISHLT. 2 International Conference on Respiratory Physiotherapy ARIR Genova, March 21 23, 2013
LUNG TRANSPLANTS The Journal of Heart and Lung Transplantation, 2012 2 International Conference on Respiratory Physiotherapy ARIR Genova, March 21 23, 2013 LUNG TRANSPLANTATION:STATE OF THE ART L. Santambrogio
More informationCHAPTER 5. Paediatric Renal Replacement Therapy
24th Report of the CHAPTER 5 Paediatric Renal Replacement Therapy Lee Ming Lee Lim Yam Ngo Lynster Liaw Chiew Tung Susan Pee Yap Yok Chin Wan Jazilah Wan Ismail 24th Report of the SECTION A: RRT PROVISION
More informationNATIONAL NEUROLOGY REGISTRY Stroke Notification Form
TIOL NEUROLOGY REGISTRY Stroke tification Form Instruction Where check boxes are provided, check ( ) one or more boxes Where radio buttons are provided, check ( ) one box only For Office Use only ID Centre
More information1. Discuss the basic pathophysiology of end-stage liver and kidney failure.
TRANSPLANT SURGERY ROTATION (PGY1, 2) A. Medical Knowledge Goal: The resident will achieve a detailed knowledge of the evaluation and treatment of a variety of disease processes. The resident will be exposed
More informationRenal Transplant. Tony Chacon. Program Head BCIT Nephrology Nursing Program.
Renal Transplant Tony Chacon Program Head BCIT Nephrology Nursing Program Email: tony_chacon@bcit.ca Summary of CNA Renal Transplant Competencies Potential contraindications to renal transplant. Assessment/selection
More informationPancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP
Pancreas and Pancreas-Kidney Transplantation By: Kay R. Brown, CLCP Pancreas transplant recipients are usually under age 50. The majority of pancreas transplants are performed on diabetics, who are generally
More informationPost Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.
Post Transplant Immunosuppression: Consideration for Primary Care Sameh Abul-Ezz, M.D., Dr.P.H. Objectives Discuss the commonly used immunosuppressive medications and what you need to know to care for
More information2014/LSIF/PD/008 Building Blocks and Challenges to Implementing a National Blood Program in Malaysia
2014/LSIF/PD/008 Building Blocks and Challenges to Implementing a National Blood Program in Malaysia Submitted by: Malaysia Policy Dialogue and Workshop on Attaining a Safe and Sustainable Blood Supply
More informationHeart Transplant: State of the Art. Dr Nick Banner
Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationTransplant in Pediatric Heart Failure
Transplant in Pediatric Heart Failure Francis Fynn-Thompson, MD Co-Director, Center for Airway Disorders Surgical Director, Pediatric Mechanical Support Program Surgical Director, Heart and Lung Transplantation
More informationImplantable Ventricular Assist Devices and Total Artificial Hearts. Policy Specific Section: June 13, 1997 March 29, 2013
Medical Policy Implantable Ventricular Assist Devices and Total Artificial Hearts Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationNephrology Dialysis Transplantation
Nephrol Dial Transplant (1999) 14: 394 399 Original Article Nephrology Dialysis Transplantation Reduced kidney transplant rejection rate and pharmacoeconomic advantage of mycophenolate mofetil Rudolf P.
More informationAccess to Heart and Lung Transplantation for Minority Populations. Cedric Sheffield, MD
Access to Heart and Lung Transplantation for Minority Populations Cedric Sheffield, MD End Stage Heart Failure Magnitude of the Problem CHF is America s Highest - Volume 700,000 600,000 500,000 400,000
More informationAnoxic insult Stroke/Cerebrovascular accident
Page 1 of 5 Patient Details Hidden Show Show/Hide Annotations Stickies: Toggle All Toggle Open Toggle Resolved Form 10: Death Print this Form t Started 1 Date of Death MM/DD/YYYY 2 Primary cause of death
More informationIndex. Note: Page numbers of article titles are in boldface type. Heart Transplantation
Heart Transplantation Index Note: Page numbers of article titles are in boldface type. Accelerated graft atherosclerosis (AGA), post heart transplantation, 73-74 Acute rejection, of heart, in adults, 70
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationThe Japanese Organ Transplant Act came into effect
298 FUKUSHIMA N et al. Circ J 2017; 81: 298 303 doi: 10.1253/circj.CJ-16-0976 REPORT OF HEART TRANSPLANTATION IN JAPAN Registry Report on Heart Transplantation in Japan (June 2016) Norihide Fukushima,
More informationPost Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ
Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ Art of Good Cooking Good Ingredient Good donor + OK recipient Good technique Good team Good timing Good
More informationControversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital
Controversies in Renal Transplantation Patrick M. Klem, PharmD, BCPS University of Colorado Hospital The Controversial Questions Are newer immunosuppressants improving patient outcomes? Are corticosteroids
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationOntario s Referral and Listing Criteria for Adult Heart Transplantation
Ontario s Referral and Listing Criteria for Adult Heart Transplantation Version 3.0 Trillium Gift of Life Network Adult Heart Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The
More informationTransplantation in Australia and New Zealand
Transplantation in Australia and New Zealand Matthew D. Jose MBBS (Adel), FRACP, FASN, PhD (Monash), AFRACMA Professor of Medicine, UTAS Renal Physician, Royal Hobart Hospital Overview CKD in Australia
More informationTransplant Overview. Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005
Transplant Overview Timothy J. Schroeder President and CEO CTI Clinical Trial and Consulting Services November 10, 2005 CTI Clinical Trial and Consulting Services Drug Development Company focused in key
More informationChronic Kidney Disease & Transplantation. Paediatrics : 2004 FRACP
Chronic Kidney Disease & Transplantation Paediatrics : 2004 FRACP ANZDATA Registry Mode of First Treatment - Paediatric 14 12 10 8 6 4 2 0 0-4 y 5-9 y 10-14 y 15-19 y Hospital CAPD Hospital HD Hospital
More informationSymposium. Post-operative Management Of Pediatric Heart Transplantation : A Brief Review
DOI-10.21304/2018.0503.00394 Symposium Post-operative Management Of Pediatric Heart Transplantation : A Brief Review Balakrishnan KR*, Suresh KG**, Muralikrishna T***, Suresh Kumar R **** *Director, Cardiac
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationCases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center
Cases: CMV, HCV, BKV and Kidney Transplantation Simin Goral, MD University of Pennsylvania Medical Center Disclosures Grant support: Otsuka Pharmaceuticals, Astellas Pharma, Angion, AstraZeneca, and Kadmon
More informationBK Viral Infection and Malignancy in Renal Transplantation ~A Case History~
BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~ Mariko Toyoda, MD Department of Nephrology, Japanese Red Cross Kumamoto Hospital Statement of Disclosure The author does not
More informationSurgical Options for Advanced Heart Failure
Surgical Options for Advanced Heart Failure Benjamin Medalion, MD Director, Transplantation and Heart Failure Surgery Department of Cardiothoracic Surgery Rabin Medical Center, Beilinson Hospital Heart
More informationHeart and Lung Transplantation in the United States,
American Journal of Transplantation 2007; 7 (Part 2): 1390 1403 Blackwell Munksgaard No claim to original US government works Journal compilation C 2007 The American Society of Transplantation and the
More informationOrgan Procurement and Transplantation Network
OPTN Organ Procurement and Transplantation Network POLICIES This document provides the policy language approved by the OPTN/UNOS Board at its meeting in June 2015 as part of the Operations and Safety Committee
More informationFellows Conference 01/21/2016
Fellows Conference 01/21/2016 Outline Basics of transplantation Benefits of transplantation Immunosuppressive medications Anatomy of Renal Transplantation Recipient Selection General medical condition.
More informationConsidering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol
Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol Patient details Name DOB ESRD Other history Mr. B.I.B. 12 January 1975 (34yo) Membranous GN
More informationHeart Transplantation in the United States,
American Journal of Transplantation 29; 9 (Part 2): 932 941 Wiley Periodicals Inc. No claim to original US government works Journal compilation C 29 The American Society of Transplantation and the American
More information2017 Year End Review
Number Of Patients End Review Transplants 9 9 Kidney Kidney Pancreas Pancreas Liver Heart Number of Patients on WaitList as of..9 Kidney Kidney Pancreas Pancreas Liver Heart Number of Donors Number of
More informationGUIDELINES ON RENAL TRANSPLANTATION
46 GUIDELINES ON RENAL TRANSPLANTATION T. Kälbe (chairman), M. Lucan, G. Nicita, R. Sells, F.J. Burgos Revilla, M. Wiesel Introduction The number of patients registered as starting end-stage renal disease
More informationSolid Organ Transplantation
LOGO Solid Organ Transplantation Dr. Mohammad Taraz Clinical Pharmacist June 2011 2 Introduction Solid organ transplantation is a well accepted therapeutic option for patients with end-stage kidney, liver,
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationThree Sides to Allocation. ECD Extended Criteria Donor
Kidney Allocation- Optimal Use of Deceased Donors The New US System..and impact on wait list management Three Sides to Allocation Justice Peter G Stock MD, PhD Utility Efficiency Standard Criteria Donor
More informationAljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia
Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia Immunosuppression in kidney transplantation Aljoša Kandus Renal Transplant Center, Department
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationSolid Organ Transplantation
Solid Organ Transplantation Ronald H. Kerman, PhD Professor of Surgery Director, Histocompatibility and Immune Evaluation Laboratory Division of Immunology & Organ Transplantation The University of Texas
More informationPolicy Specific Section: May 16, 1984 April 9, 2014
Medical Policy Heart Transplant Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Transplant Original Policy Date: Effective Date: May 16, 1984 April 9, 2014 Definitions
More informationheart OPTN/SRTR 2013 Annual Data Report:
heart waiting list... deceased donation... transplant... donor-recipient matching outcomes... pediatric transplant... transplant center maps... 6 11 12 1 16 19 2 M. Colvin-Adams1,2, J. M. Smith1,3, B.
More informationWhat is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham
What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham SYMPHONY Study Ekberg et al. NEJM 2008 Excluded: DCD kidneys; CIT>30hours;
More informationHeart Transplant Family Education Class
Heart Transplant Family Education Class Celebrating 30 years History of Heart Transplantation First successful adult heart transplant in United States- January 6, 1968 First heart transplant at OHSU -
More informationNephrology Grand Rounds
Nephrology Grand Rounds PTLD in Kidney Transplantation Charles Le University of Colorado 6/15/12 Objectives Background Pathogenesis Epidemiology and Clinical Manifestation Incidence Risk Factors CNS Lymphoma
More informationUnderstanding the Pediatric Ventricular Assist Device
Understanding the Pediatric Ventricular Assist Device W. James Parks, MSc., MD Pediatric Cardiologist Assistant Professor of Pediatrics and Radiology Children s Healthcare of Atlanta Sibley Heart Center
More informationHeart Transplantation
Heart Transplantation Abbas Ardehali, M.D., F.A.C.S. Professor of Surgery and Medicine, Division of Cardiac Surgery William E. Connor Chair in Cardiothoracic Transplantation Director, UCLA Heart, Lung,
More information2012 Year In Review In Review. Number of Patients on WaitList as of Number Of Transplants Year. Number Of Patients
Number Of Patients Number Of Transplants In Review In Review Kidney Kidney Pancreas Pancreas Liver Heart Number of Patients on WaitList as of.. Kidney Kidney Pancreas Liver Heart Number of Donors Number
More informationIncreased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation
Increased Early Rejection Rate after Conversion from Tacrolimus in Kidney and Pancreas Transplantation Gary W Barone 1, Beverley L Ketel 1, Sameh R Abul-Ezz 2, Meredith L Lightfoot 1 1 Department of Surgery
More informationTransplant Athlete Medical Form 2019 World Transplant Games, Newcastle Gateshead
Transplant Athlete Medical Form 2019 World Transplant Games, Newcastle Gateshead Please note that you should only use this form for collecting your medical data because you MUST input all the data online
More information2014 Year End Review
End Review Transplants Kidney Kidney Pancreas Pancreas Liver Heart Number of Patients on WaitList as of.. 99 Number Of Patients 9 Kidney Kidney Pancreas Liver Heart Organ Donor Statistics Atlantic Canada
More informationTargeted Adverse Event (ADV)
North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0; 06-20-13 1.
More informationA Tolerance Approach to the Transplantation of Vascularized Tissues
A Tolerance Approach to the Transplantation of Vascularized Tissues The 9th New Jersey Symposium on Biomaterials Science and Regenerative Medicine October 29-31, 2008 David H. Sachs, M.D. Harvard Medical
More informationBriefing to Members of Parliament
Briefing to Members of Parliament 22.03.2012 Copyright HDC 2012 Overview of the Global Halal Market Key drivers of growth 1. Sizeable and growing Muslim population 2. Growing economic development in Muslim
More informationPatient Name: MRN: DOB: Treatment Location:
Page 1 of 5 I. TO (Required) This Section is required to be completed by all patients who undergo kidney transplant surgery. I hereby consent to and authorize Dr. and his/her assistant(s), including supervised
More informationAttending Physician Statement- Heart Attack
Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Heart attack / Cardiomyopathy
More informationHOTA PARAMETERS OF CASE SUBMISSION FOR LIVER TRANSPLANT
HOTA PARAMETERS OF CASE SUBMISSION FOR LIVER TRANSPLANT 1. COMPLETE AND DETAILED INTRODUCTION OF BOTH THE PATIENT AND THE INCLUDING: 1- COMPLETE PRESENT ADDRESS 2- CELL NUMBERS OF THE PATIENT, THE AND
More informationHearts With Cardiac Arrest History Safe For Transplant In The Context Of Donor And Recipient Factors
Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine January 2015 Hearts With Cardiac Arrest History Safe For Transplant
More informationJennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio
Biventricular Heart Failure Advanced Treatment Options at The Cleveland Clinic Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio I have no disclosures. Examine respiratory and
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More informationWho and When to Refer for a Heart Transplant
Who and When to Refer for a Heart Transplant Dr Jayan Parameshwar Consultant Cardiologist Papworth Hospital BSH 24 th November 2017 BSH Annual Autumn Meeting 2017 Presentation title: Who and when to refer
More informationTRANSPLANTATION IN DIABETIC PATIENTS. A.Tarik Kizilisik, MD, MSc, FACS, FICS Director & Primary Transplant Surgeon Lutheran Transplant Center
TRANSPLANTATION IN DIABETIC PATIENTS A.Tarik Kizilisik, MD, MSc, FACS, FICS Director & Primary Transplant Surgeon Lutheran Transplant Center Diabetes is the pandemic of the new millennium 24 million diabetics
More informationBetter than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct
Better than Google- Click on Immunosuppression Renal Transplant David Landsberg Oct 3 2008 OUTLINE History of Immunosuppression Trends in Immunosupression FK vs CYA Steroid Minimization CNI Avoidance Sirolimus
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationIntroducing the COAPT Trial
physician INFORMATION Eligible patients Symptomatic functional mitral regurgitation 3+ Not suitable candidates for open mitral valve surgery NYHA functional class II, III, or ambulatory IV Introducing
More informationSurgery and device intervention for the elderly with heart failure: assessing the need. Devices and Technology for heart failure in 2011
Surgery and device intervention for the elderly with heart failure: assessing the need Devices and Technology for heart failure in 2011 Assessing cardiovascular function / prognosis (in the elderly): composite
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationAcute heart failure: ECMO Cardiology & Vascular Medicine 2012
Acute heart failure: ECMO Cardiology & Vascular Medicine 2012 Lucia Jewbali cardiologist-intensivist 14 beds/8 ICU beds Acute coronary syndromes Heart failure/ Cardiogenic shock Post cardiotomy Heart
More informationTerms of Reference (TOR)
Terms of Reference (TOR) Terms of Reference for MSM Operational Research including Consultation with Key Stakeholders/Focus Group Discussions, Mapping of Currently Available Services, and Assessment of
More informationHow to mend a broken heart: transplantation or LVAD?
SCDU DI CARDIOCHIRURGIA Università degli Studi di Torino Ospedale S. Giovanni Battista Direttore: Prof. Mauro Rinaldi How to mend a broken heart: transplantation or LVAD? Massimo Boffini Mauro Rinaldi
More informationCABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock
CABG for ischemic cardiomyopathy, post myocardial infarction and cardiogenic shock Yoshiya Toyoda, MD, PhD William Maul Measey Professor of Surgery Chief, Cardiovascular Surgery Surgical Director, Mechanical
More informationCigarette Smoking in Renal Transplant Recipients
Cigarette Smoking in Renal Transplant Recipients J Am Soc Nephrol 11: 753 759, 2000 BERTRAM L. KASISKE and DAGMAR KLINGER Department of Medicine, Division of Nephrology, Hennepin County Medical Center,
More informationTable S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationTargeted Adverse Event (ADV)
Page 1 of 35 North American Pediatric Renal Trials Collaborative Studies Production Release 5.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0;
More information10WS Solid Organ Transplant
10WS Solid Organ Transplant Table of Contents 1. Cross Coverage Tips... Page 2 2. Donor Protocols Induction... Page 2 Maintenance... Page 3 Mycophenolate Mofetil... Page 3 Tacrolimus... Page 3 Cyclosporine...
More information